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Abstract
Background: HIV-related stigma significantly impacts HIV care engagement, including in prevention of mother-to-
child transmission of HIV (PMTCT) programs. Maisha is a stigma-based counseling intervention delivered during the
first antenatal care (ANC) visit, complementing routine HIV counseling and testing. The goal of Maisha is to
promote readiness to initiate and sustain treatment among those who are HIV-positive, and to reduce HIV
stigmatizing attitudes among those who test negative.
Methods: A pilot randomized control trial will assess the feasibility and acceptability of delivering Maisha in a
clinical setting, and the potential efficacy of the intervention on HIV care engagement outcomes (for HIV-positive
participants) and HIV stigma constructs (for all participants). A total of 1000 women and approximately 700 male
partners will be recruited from two study clinics in the Moshi municipality of Tanzania. Participants will be enrolled
at their first ANC visit, prior to HIV testing. It is estimated that 50 women (5%) will be identified as HIV-positive.
Following consent and a baseline survey, participants will be randomly assigned to either the control (standard of
care) or the Maisha intervention. The Maisha intervention includes a video and counseling session prior to HIV
testing, and two additional counseling sessions if the participant tests positive for HIV or has an established HIV
diagnosis. A subset of approximately 500 enrolled participants (all HIV-positive participants, and a random selection
of HIV-negative participants who have elevated stigma attitude scores) will complete a follow-up assessment at 3
months. Measures will include health outcomes (care engagement, antiretroviral adherence, depression) and HIV
stigma outcomes. Quality assurance data will be collected and the feasibility and acceptability of the intervention
will be described. Statistical analysis will examine potential differences between conditions in health outcomes and
stigma measures, stratified by HIV status.
Discussion: ANC provides a unique and important entry point to address HIV stigma. Interventions are needed to
improve retention in PMTCT care and to improve community attitudes toward people living with HIV. Results of the
Maisha pilot trial will be used to generate parameter estimates and potential ranges of values to estimate power for
a full cluster-randomized trial in PMTCT settings, with extended follow-up and enhanced adherence measurement
using a biomarker.
Trial registration: ClinicalTrials.gov, NCT03600142. Registered on 25 July 2018.
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Background
Prevention of mother-to-child transmission (PMTCT)
programming serves as an essential entry point for HIV
testing and linkage to care, and has the potential to
eliminate the incidence of vertical mother-to-child trans-
mission. Under the Option B+ guidelines for PMTCT
recommended by the World Health Organization, uni-
versal HIV testing in antenatal care (ANC) is followed
by initiation of lifelong antiretroviral therapy (ART) for
pregnant and breastfeeding women living with HIV [1].
Despite the global roll-out of Option B+ programs, re-
tention in HIV care during the pregnancy and postpar-
tum periods has been suboptimal [2, 3].
HIV-related stigma — whether anticipated, internalized,
or enacted — has a profound impact on decisions related
to HIV [4, 5] and is a primary factor influencing linkage
and retention in PMTCT programs [6–8]. In addition,
stigma undermines the quality of life of people living with
HIV (PLWH), contributing to emotional distress and so-
cial alienation [5]. Among HIV-negative individuals, mis-
information and prejudicial attitudes about HIV can fuel
stigma and contribute to discrimination against PLWH,
and can lead individuals to avoid or delay HIV testing [9].
Social environments where enacted stigma occurs, or
where stigma is strongly anticipated, contribute to inter-
nalized feelings of shame among PLWH and undermine
the success of PMTCT programs [10, 11].
Entry into ANC provides a unique opportunity to reach
pregnant women and their male partners to reduce
community-level HIV stigma and to improve linkage to
and retention in HIV care for individuals living with HIV.
Addressing HIV stigma at the first ANC visit can help
women who test positive to overcome stigma-related bar-
riers to the initiation and maintenance of HIV care, and
can help women who know their status to cope with HIV-
related stigma during pregnancy and the transition to
PMTCT services. Additionally, partner HIV testing during
ANC provides a unique opportunity to reach men, in
order to address HIV stigmatizing attitudes and improve
men’s linkage to HIV care. Long-term HIV care engage-
ment for both women and men has important implica-
tions for health outcomes, quality of life, and the risk of
future transmission to their child or others.
The goal of this study is to conduct a pilot evaluation of a
brief, scalable counseling intervention called Maisha, which
addresses HIV stigma at entry into ANC. The study will be
conducted in Moshi, Tanzania. The intervention includes
up to three sessions (one session prior to HIV testing, and
two additional sessions for those who test positive for HIV).
Male partners will be invited to attend Maisha 1 and
Maisha 2; Maisha 3 is for women only. The intervention
content is based on principles of cognitive-behavioral ther-
apy (addressing automatic negative thoughts about the self,
future, and the world/others) to address and mitigate
multiple forms of HIV stigma (internalized, anticipated,
and enacted). The intervention approach is novel because it
addresses HIV stigma at a key, early, juncture of care time
point, and, among those who are HIV-negative, it promotes
acceptance and empathy toward PLWH during the height-
ened emotional period of HIV testing.
Methods
Study design
The study is a pilot randomized control trial aimed at
determining the feasibility, acceptability, and potential
efficacy of an HIV stigma counseling intervention for
individuals entering antenatal care (ANC). The study has
two parallel groups: control and intervention. The con-
trol group will receive standard of care from the clinical
sites; the intervention group will receive standard of care
paired with up to three Maisha counseling sessions. The
allocation ratio for these parallel groups is 1:1. Table 1
summarizes key elements of the study, and Fig. 1 illus-
trates participant flow through the study.
Ethical approval and registration
The study has been approved by the ethical review com-
mittees at Duke University, Kilimanjaro Christian Med-
ical Center, and the National Institute for Medical
Research in Tanzania. The trial is registered at Clinical-
Trials.gov (NCT03600142).
Study setting
The study will be conducted in two government health
facilities in Moshi municipality, Tanzania. The Majengo
and Pasua Health Centers together see approximately
2500 pregnant women per year; an estimated 4.8% of
pregnant women seen at the clinics are living with HIV.
All patients are required to have an HIV test at entry to
ANC, unless they present a clinic card confirming that
they have previously tested positive for HIV. Pregnant
patients are strongly encouraged to bring their male
partner to the first ANC visit for pregnancy education as
well as partner HIV testing.
Participants
The study will enroll 1000 women into the study.
Women will be enrolled at entry into ANC, prior to re-
ceiving a routine HIV text; of the 1000 female partici-
pants, we expect that approximately 50 will be
established or newly diagnosed as HIV-positive. Based
on record review at the study clinics, we estimate that
70% of female participants will attend the ANC visit with
their male partner, allowing for an enrollment of up to
700 men. The sample size was selected in order to have
adequate power to detect differences in our outcome of
HIV stigma attitudes for our HIV-negative clients, and
Watt et al. Trials          (2019) 20:807 Page 2 of 13
to have pilot feasibility data related to outcomes for
HIV-positive clients [12, 13].
Participants will be enrolled prior to attending their
ANC appointment, which is where routine HIV testing
occurs. Following written consent to participate in the
study, participants will complete the baseline survey and
be randomized to a condition. Following the survey and
Maisha 1 (if randomized to intervention arm), they will
return to the clinic for standard of care services, includ-
ing HIV testing.
Participants will be eligible for the study if they meet
the following criteria:
 Minimum 18 years of age
 Women: pregnant and attending first ANC
appointment for current pregnancy
Table 1 Study summary (template adapted from the World Health Organization Trial Registration Data Set)
Data category Information
Title A Stigma Reduction Intervention at Time of Entry into Antenatal Care to Improve
PMTCT Services in Tanzania (Maisha)
Primary registry and trial identifying number ClinicalTrials.gov
NCT03600142
Registered July 25, 2018
Secondary identifying numbers R21 TW011053 (US NIH Grant/Contract)
Primary funder Fogarty International Center (NIH)
Contact for public queries Melissa Watt, PhD
melissa.watt@utah.edu
Countries of recruitment Tanzania
Health condition(s) or problem(s) studied HIV care engagement
HIV stigma
Key inclusion and exclusion criteria Ages eligible: 18 years and older
Sexes eligible: all
Accepts healthy volunteers: yes
Inclusion criteria:
18 years of age or older
If female: pregnant and attending first antenatal care (ANC) appointment for the
current pregnancy at one of the two study sites
If male: accompanying an enrolled woman to her first ANC appointment.
Exclusion criteria:
Impaired mental status
Does not speak Swahili
Study type Pilot feasibility trial
Allocation: randomized
Allocation ratio: 1:1
Intervention model: parallel assignment
Date of first enrollment April 8, 2019
Target sample size 1700 participants
Recruitment status Recruiting
Primary outcome(s) HIV care retention (female HIV-infected participants only) (time frame: post assessment
(3 months after enrollment))
Internalized HIV stigma (HIV-infected participants only) (time frame: post assessment
(3 months after enrollment))
Attitudes toward people living with HIV (HIV-uninfected participants only) (time frame:
post assessment (3 months after enrollment))
Key secondary outcomes ART adherence (HIV-infected participants only) (time frame: post assessment
(3 months after enrollment))
Depression (HIV-infected participants only) (time frame: post assessment
(3 months after enrollment))
HIV disclosure (HIV-infected participants only) (time frame: post assessment
(3 months after enrollment))
Anticipated HIV stigma (all participants) (time frame: post assessment
(3 months after enrollment))
Linkage to HIV care (male HIV-infected participants only) (time frame: post assessment
(3 months after enrollment))
Willingness to test for HIV in the future (HIV-uninfected participants only)
(time frame: post assessment (3 months after enrollment))
ART antiretroviral therapy, HIV human immunodeficiency virus, NIH National Institutes of Health, PMTCT prevention of mother-to-child transmission
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 Men: accompanying a partner to her first ANC
appointment (note: the partner must be enrolled for
the man to be eligible to participate)
 Able to understand and speak Kiswahili
 Able to provide consent
Procedures
Screening and recruitment
First ANC attendees and their partners will be identified
in the clinic waiting room by the clinic nurses. The
nurses, in cooperation with research staff, will provide a
brief description of the research activities, including the
time commitment. Individuals who are interested in
learning more will meet with the research team in a
private research office, either alone or with their partner.
The research staff will confirm that the individual(s)
meet the eligibility requirements, will clearly explain the
study, and will obtain written informed consent. No
biological specimens will be collected in this trial; there-
fore, consent for specimen storage is not applicable.
Contact information will be gathered from participants
in order to facilitate the scheduling of follow-up assess-
ments; this information will be securely stored in a locked
file cabinet, separate from other participant information
and data, and accessed by authorized study staff only.
Baseline data collection
After providing consent, all participants will complete a
structured survey using audio computer-assisted self-
interview (ACASI) technology on tablets running Ques-
tionnaire Development System (QDS) software. The
ACASI modality can ensure participant privacy and
improve data validity by minimizing social desirability
bias [14]. Participants will complete the assessment on
individual tablets where they can read (on the screen)
and listen (through recorded audio) to the questions and
Fig. 1 Study flowchart. HIV human immunodeficiency virus
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response options in Kiswahili. As response options are
read aloud, the corresponding text will light up on the
screen. Participants can select their response using the
tablet touch screen. The computerized assessments are
programmed to skip questions that are not applicable
based on previous question responses. Validity check
items (e.g., “For this question, choose strongly agree”) are
included throughout to assess for data quality and par-
ticipant attentiveness. A research staff member will be
present in the room to answer any questions and pro-
vide assistance as needed. The data files will be securely
transferred each day to the local data manager, who will
store the files in a centralized location on a secured drive
and review the files on a weekly basis for any quality is-
sues. Stored data will be identified by a unique ID only,
with access limited to authorized investigators and staff.
Allocation
Upon completion of the baseline assessment, the partici-
pant will be randomized to receive either the standard of
care HIV testing and counseling or the standard of care
plus the Maisha intervention. Female participants will be
randomized at a 1:1 ratio using a block randomization
method (10 per block) to ensure equal sample sizes by
condition and to manage the flow of participants to the
intervention condition. The allocation sequences will be
prepared ahead of time by a statistician using an online
randomization program (www.sealedenvelope.com). Se-
quences will be generated separately for each of the two
study clinics. Study staff who are not involved in partici-
pant enrollment, assignment, assessment, or delivery of
the intervention will prepare sealed, opaque envelopes for
each study ID containing the randomized condition as-
signment. After a female participant completes the base-
line assessment, she will open the envelope marked with
her corresponding study ID and will learn her assignment;
male participants will be assigned to the same condition
as their partners. Participants will not be blinded to their
allocation, as all participants will be aware of the add-
itional time and activity commitments required as part of
participation in the intervention condition. Since the trial
is unblinded, emergency unblinding is not applicable. The
research staff who give the participants their assignment
envelopes will not know the randomization sequence until
the conditions are assigned. Health care personnel at the
study clinics will not be informed of participants’ study
conditions, in order to prevent interference in standard of
care delivery.
Experimental conditions
Control: standard of care HIV testing and counseling
Participants randomized to the control condition will re-
ceive the standard HIV testing and counseling protocol
in the clinic, which is administered by clinic nurses. The
standard of care was chosen as the comparator in order
to evaluate whether the Maisha intervention has an im-
pact above and beyond the standard clinic procedures
for HIV counseling and testing. According to the
Tanzania PMTCT guidelines, HIV pretest counseling
should provide education about HIV and prepare a
woman (and her partner, if present) for HIV testing [15].
For anyone who tests positive for HIV, counseling
should help the woman/couple to accept an HIV test re-
sult and discuss implications for treatment. HIV-infected
women should be registered for PMTCT and immedi-
ately initiated on ARVs. HIV-infected men should be re-
ferred to the HIV care and treatment clinic (CTC) for
same-day initiation of ARVs.
Intervention: standard of care and Maisha Participants
randomized to the intervention condition will attend the
standard of care HIV testing and counseling, and will also
receive the Maisha intervention. Maisha is a brief, scalable,
theory-based counseling intervention that addresses HIV
stigma at entry into antenatal care (ANC) and includes up
to three counseling sessions. The intervention model com-
bines a stigma framework with principles of cognitive-
behavioral therapy to address and mitigate the impact of
stigma on health outcomes. In Earnshaw and Chaudoir’s
HIV Stigma Framework, internalized, anticipated, and
enacted stigma all intersect to undermine health-seeking
behaviors [4, 16]. In developing the intervention framework,
we observed that these components of stigma track onto
the CBT “cognitive triad” of negative beliefs about oneself,
the future, and others/the world [17]. Thus, the Maisha
intervention addresses these three forms of stigma using
principles of cognitive-behavioral therapy and formative
work by Tshabalala and Visser [16, 18].
Upon entry to ANC (for most, prior to learning their
HIV status), we will deliver information, present the lived
experiences of PLWH using a video, and promote self-
reflection about community attitudes related to HIV.
Participants will examine how community perceptions
influence their beliefs about PLWH, including prejudicial
beliefs that contribute to self-stigma in the event of a posi-
tive test. In Maisha 2 and 3, with participants who are
HIV-positive (either presenting to ANC knowing their
status or getting a new diagnosis of HIV), we will review
the video content and provide additional structured coun-
seling to address the difficult emotions and cognitions
often associated with a positive status. Through linkage to
the video, we will use Beck’s interventions for cognitive
bias [19, 20] as well as Third Wave behavioral concepts
[21, 22] to address one’s automatic negative thoughts
about the self (internalized HIV stigma), the future (antici-
pated HIV stigma), and the world (enacted stigma). Inter-
vention techniques include recognizing and reframing
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cognitive distortions, helping individuals to develop a
positive self-schema, and promoting personal acceptance
and value-driven behavior to reduce stigma and encourage
positive HIV care engagement (Fig. 2). Table 2 provides
an overview of the Maisha intervention.
The development of the Maisha intervention was in-
formed by our team’s previous research [2, 3, 23], qualita-
tive interviews with patients and health care providers,
and input from a study advisory board. In order to develop
the video content, we engaged the local community advis-
ory group, comprising individuals who were living with or
affected by HIV. These “expert patients” helped us to de-
velop the video, which tells the story of a pregnant woman
and her husband who both test positive for HIV and take
steps to cope with the diagnosis. The actors for the video
were selected from the community advisory group, and
participated in the iterative refinement of the script during
filming. Following the production of the video and the de-
velopment of the intervention scripts, we conducted a trial
run of the intervention with eight participants recruited
from the ANC. Their input was elicited, which contrib-
uted to further modifications in the final intervention.
The Maisha intervention will be delivered by Bache-
lor’s-level counselors who have social work or counseling
backgrounds. Counselors will receive a minimum of 2
weeks of training on counseling techniques and the inter-
vention content, and thereafter will receive at least 1 h per
week of clinical supervision, with the opportunity for add-
itional supervision as needed. The counseling sessions will
take place in a private research office at the clinic site.
Intervention fidelity The intervention counselor will
complete a quality assurance (QA) and process rating
form after each session. This form records issues raised
in the session, coverage of session content, and feasibility
of delivery. All intervention sessions will be recorded
(with participant consent), and each week 1 session from
each counselor will be reviewed during a group supervi-
sion session. Using a structured form [24], the coun-
selors and supervising staff will assess the recorded
sessions for intervention fidelity and presence of core
components of counseling. During the group supervision
session, the team will review the recording to discuss
challenges and provide additional feedback and training.
Scheduling For participants who are assigned to receive
Maisha 2 and Maisha 3, the counselor will aim to deliver
Maisha 2 on the same day as enrollment and Maisha 1
(i.e., the day of the first ANC appointment). If this is not
possible (e.g., if the participant does not return after testing,
or the participant does not have time to complete the
session that day), the counselor will attempt to schedule the
session for another day, ideally within 72 h. Maisha 3 will
be scheduled approximately 2 weeks after completing
Maisha 2. In order to reduce the burden on participants
and improve attendance, the counselor will try to schedule
Maisha 3 on the same day as the participant’s next clinic
appointment. The counselor will call participants to remind
them of upcoming sessions. If a participant misses a sched-
uled session, the counselor will call to follow-up and
reschedule if possible. Participants may choose to stop at-
tending Maisha sessions or withdraw from the study at any
time.
During the study period, participants will continue with
the standard antenatal care, which includes routine HIV
pretest and posttest counselling for unknown status. The
intervention is intended to supplement, not replace,
existing clinical care, and therefore does not impact use of
or access to routine medical care.
Follow-up assessment
A subset of participants (approximately 300 women and
200 men) will be selected to complete a follow-up assess-
ment 3months after completing the baseline assessment.
Fig. 2 Intervention theoretical framework. ANC antenatal care, ART antiretroviral therapy, HIV human immunodeficiency virus, PLWH people living
with HIV/AIDS, PMTCT prevention of mother-to-child transmission
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Table 2 Overview of the Maisha intervention
Session information Content Goals
Maisha 1
Population: all intervention participants (women only or
couples); separate guides for participants with unknown
HIV status and participants with known HIV diagnosis
Timing: before standard of care ANC visit
Watch 8-min video telling the story of Salma and
Bahati, a couple who test for HIV at their antenatal
care visit and learn how to navigate their diagnosis
Review video and discuss topics related to both
Salma and participant:
• Feelings during HIV testing
• Thoughts about the future
• Anxieties related to HIV testing
• Importance of HIV care engagement
• Supportive individuals
Introduce and discuss the three types of stigma:
internalized, enacted, anticipated
Final messages
• If you test positive, there are medications available
and people who can support you
• If you test negative, you can be a source of support
for other people who have HIV
For participants with a known HIV diagnosis, the
session involves a discussion of how the video and
types of stigma relate to the participants’ own
experiences of living with HIV
• Normalize HIV and increase empathy
for people living with HIV
• Raise consciousness regarding HIV
stigma, and rethink stigmatizing
attitudes
• Prepare participants for HIV testing
and acceptance of a possible HIV
diagnosis
Maisha 2
Population: all intervention participants with an HIV
diagnosis (couples attend if at least one person in the
couple has an HIV diagnosis); separate guides for new HIV
diagnoses and established HIV diagnoses
Timing: same day as Maisha 1, after ANC visit
Link back to video to provide hope for the future
and address the three types of HIV stigma:
Internalized stigma
• Acknowledge negative emotions
• Reassure about accepting one’s HIV status with time
Anticipated stigma
• Acknowledge worries
• Reassure about their future
Enacted stigma
• Acknowledge that it may take time to disclose and
get support
Identify values and link to adherence/care
engagement
Final messages
• Acceptance is a process that takes time
• Your values can help you commit to taking
treatment and attending the clinic
• Address immediate stigma-related
concerns and provide reassurance
• Create commitment to treatment and
a plan to return to the same clinic for
the next HIV appointment
Maisha 3
Population: all HIV-infected female intervention
participants (women only); separate guides for
new HIV diagnoses and established HIV diagnoses
Timing: 2 weeks after Maisha 2
Link back to video to help the client develop an
action plan, addressing the three types of stigma:
Internalized stigma
• Discuss feelings about oneself as someone living
with HIV
• Action plan for how one can come to accept self
as someone living with HIV
Anticipated stigma
• Discuss worries related to attending the clinic
(especially related to others learning about one’s
HIV status)
• Action plan for attending clinic and taking ARVs
Enacted stigma
• Discuss any disclosures and support
• Action plan for disclosing and/or harnessing
support to stay in care
Discuss HIV and personal care, including:
• Check-in on taking medication
• Establish connections between thoughts and
feelings using a CBT model; discuss coping
mechanisms
• Introduce a mindfulness/breathing exercise
• Discuss challenges and make a commitment to care
Final messages
• Just taking the step to be here at this session and
at the clinic is an important one and something to
be proud of
• Acknowledging and addressing worries can help us
stay positive and find support
• It is important to keep coming to care and taking
medications
• Build on the previous sessions to
prevent or reduce internalized and
anticipated stigma
• Develop strategies to cope with or
mitigate enacted stigma, while getting
support
• Develop commitment to PMTCT care,
and create a plan for overcoming
barriers to care
ANC antenatal care, ARV antiretroviral, CBT cognitive-behavioral therapy, HIV human immunodeficiency virus, PMTCT prevention of mother-to-child transmission
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All HIV-positive participants and their partners (if enrolled)
will be contacted for follow-up. A subset of HIV-negative
participants will also be eligible for follow-up. In order to
observe changes in stigmatizing attitude scores among
HIV-uninfected participants, individuals with stigmatizing
attitude scores greater than 14 will be eligible for follow-up
assessment; of those who meet the criteria, a random 60%
will be invited for follow-up.
Participants selected for follow-up will complete a struc-
tured post assessment, following the same procedures for
ACASI-based data collection used for the baseline assess-
ment. At the end of the assessment, all Maisha interven-
tion participants will also respond to a short series of
open-ended feedback questions about the intervention;
this section of the assessment will be orally administered
and audio-recorded to fully capture participant responses.
Responses to the open-ended questions will be directly
translated into English from the audio-recording, and
entered into a REDCap database. For all HIV-positive
study participants, data on HIV care engagement will be
abstracted from their medical records and entered into
REDCap using double data entry, allowing for data quality
checks and secure data storage and transfer.
Participant tracking and retention
Research staff will conduct a daily review of the clinic
ANC logs to record the number of potentially eligible
participants who were not enrolled in the study. For
enrolled participants, the HIV test results and estimated
date of delivery will be recorded on the day of enroll-
ment. The research staff will maintain tracking logs to
record the dates when assessments and Maisha sessions
are scheduled and completed. In preparation for the
scheduled sessions, research staff will contact partici-
pants to remind them of upcoming appointments in
order to ensure retention. If participants are unreachable
or did not provide a contact number, research staff will
consult the participant’s medical record for upcoming
appointments and try to speak to them in person to
schedule a follow-up visit. All participants will receive a
transport allowance (5000 TSh = approximately 2 USD)
to facilitate their return to the clinic. For participants
who fail to return for a scheduled follow-up appoint-
ment, the reasons will be documented and collated
across participants.
Outcomes
Measures were selected based on previous research in
East Africa, including measure validation when available,
and evaluation of face validity by the Tanzanian
researchers on our team. All measures were translated
from English into Swahili and then back-translated and
discussed to reach consensus on best translation. Table 3
summarizes the outcome measures that will be assessed
at baseline and 3-month follow-up, specific to the partic-
ipant’s known HIV status.
Table 3 Outcome measures
Baseline* Post assessment (3 months)
HIV unknown HIV-positive HIV-negative
Primary outcomes
HIV-infected study participants
HIV care engagement X
Internalized stigma X
HIV-uninfected study participants
Attitudes toward PLWH X X
Secondary outcomes
HIV-infected study participants
ART adherence X
Depression (EPDS/PHQ-9) X X
HIV disclosure X
Anticipated HIV stigma X X
Linkage to care (male participants) X
HIV-uninfected study participants
Willingness to test for HIV in the future X X
Anticipated HIV stigma X X
ART antiretroviral therapy, EPDS Edinburgh Postnatal Depression Scale, HIV human immunodeficiency virus, PHQ-9 Patient Health Questionnaire, PLWH people
living with HIV/AIDS
*For women who present to antenatal care as known HIV infected, the following measures will also be done at baseline: HIV care engagement, adherence,
internalized stigma, and HIV disclosure
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Primary outcomes for HIV-positive participants
HIV care retention (women) Among female HIV-
positive participants, retention in care at 3-month follow-
up will be assessed via medical record review, with reten-
tion defined as having no more than a 60-day gap between
PMTCT visits at the study clinic or having a record of an
official transfer to another clinic [25]. We will assess dif-
ferences between conditions in the proportion retained in
care at 3months.
Internalized HIV stigma Among HIV-infected partici-
pants, internalized stigma will be self-reported, measured
by Scale A of the HIV and Abuse Related Shame Inven-
tory (HARSI) [26] plus one added item. Internalized
stigma will be measured at baseline (among individuals
with established HIV diagnoses) and 3months (among
individuals with new and established HIV diagnoses).
We will assess differences between conditions in mean
scores of internalized HIV stigma scores at 3 months.
For individuals with established HIV diagnosis, we will
control for baseline scores.
Primary outcomes for HIV-negative participants
Attitudes toward people living with HIV (PLWH) At-
titudes will be measured by self-report, using a modified
version of the Personal and Attributed Stigma Scale
(PASS) which includes two subscales: blame/judgment
and interpersonal distancing [27, 28]. The scale was
adapted to the local context based on formative qualitative
data collection and revised after a pilot of the measure
with 88 individuals. Attitudes will be measured at baseline
and 3months; individuals with a known HIV diagnosis
will not be assessed on their attitudes toward PLWH. We
will assess differences between conditions in mean atti-
tudes scores at 3months, controlling for baseline scores.
Secondary outcomes for HIV-positive participants
ART adherence Adherence to antiretroviral therapy
(ART) at the 3-month follow-up will be measured by self-
reported medication adherence; missing two or more pills
in the past 30 days (< 94% adherence) will be considered
poor adherence. We will assess differences between condi-
tions in the proportion with poor adherence at 3 months.
Depression Depression will be measured by the Edin-
burgh Postnatal Depression Scale (EPDS) [29] for women
and the Patient Health Questionnaire (PHQ-9) for male
partners [30]. Depression will be measured at baseline and
3months. We will assess differences between conditions
in mean attitudes scores at 3months, controlling for base-
line scores.
HIV disclosure HIV disclosure will be measured by self-
report of whether participants have ever disclosed their
HIV status to a person outside the heath care workers dir-
ectly involved in their antenatal and PMTCT care. HIV dis-
closure will be measured at baseline (among individuals
with established HIV diagnoses) and 3months (among in-
dividuals with new and established HIV diagnoses). We will
assess differences between conditions in the proportion
with poor adherence at 3months. For individuals with an
established HIV diagnosis, we will assess differences in the
change in proportion of participants who have disclosed
their HIV status in each condition between baseline and 3
months.
Anticipated HIV stigma For HIV-positive participants,
anticipated HIV stigma will be measured using an
adapted scale [31], which includes 16 items assessing the
degree to which PLWH expect they would experience
prejudice and discrimination from others if their status
was known. Anticipated stigma will be measured at
baseline (among individuals with established HIV diag-
noses) and 3months (among individuals with new and
established HIV diagnoses). We will assess differences
between conditions in mean scores of anticipated HIV
stigma scores at 3 months. For individuals with estab-
lished HIV diagnosis, we will control for baseline scores.
Linkage to care (men) Among HIV-positive male part-
ners, linkage to care at a care and treatment clinic (CTC)
will be self-reported at the 3-month follow-up, with link-
age to care defined as having attended any CTC appoint-
ment. We will measure differences between conditions in
the proportion of HIV-positive men attending a CTC for
HIV care at 3months.
Secondary outcomes for HIV-negative participants
Willingness to test for HIV in the future Willingness
to test for HIV in the future will be measured by self-
report of whether participants intend to test for HIV in
the next 12 months. Willingness to test for HIV will be
measured at baseline and 3months. We will assess
differences in the change in proportion of participants
who have disclosed their HIV status in each condition
between baseline and 3months.
Anticipated HIV stigma For HIV-negative partici-
pants, anticipated HIV stigma will be measured using
an adapted scale [31], which includes 16 items asses-
sing the degree to which participants would expect to
experience prejudice and discrimination if they were
to be told they were living with HIV. Anticipated
stigma will be measured at baseline and 3 months.
We will assess differences between conditions in
Watt et al. Trials          (2019) 20:807 Page 9 of 13
mean scores of anticipated HIV stigma scores at 3
months, controlling for baseline scores.
Quality assurance (QA) data
Participant satisfaction with the intervention will be
assessed at 3-month follow-up via structured and open-
ended questions about satisfaction with the intervention
and facilitator, satisfaction with the timing and length of
the sessions, ability of the intervention to address issues
specific to participant’s experience and context, and sug-
gested changes to the intervention. Intervention sessions
will be recorded and a subset of recordings will be
reviewed to assess whether core components of the
sessions were completed, and to evaluate the effective-
ness of the counselor in achieving session objectives.
Statistical analysis
Feasibility, acceptability, and potential efficacy of the
intervention
Data analysis will follow guidelines of the CONSORT
2010 statement, as extended to pilot feasibility trials
[32]. Feasibility and acceptability of the intervention and
the associated trial will be described by recruitment and
retention patterns, participant satisfaction, and fidelity of
intervention delivery. Retention will be monitored to cal-
culate the percentage of eligible intervention participants
who attend Maisha 2 and Maisha 3 and participants
who complete the 3-month assessment. The team will
document barriers to attendance for participants and will
examine differences between participants who attend and
those who do not. Participant satisfaction data at the 3-
month follow-up will be described, with > 80% satisfaction
used as a metric of acceptability. Open-ended questions
will be thematically coded to summarize participants’ per-
ceptions of the intervention, suggestions for changes, and
feasibility moving forward. The fidelity to the intervention
will be assessed by examining the percentage of compo-
nents from the Maisha session guides that are covered in
each session.
Potential efficacy will be examined by analyzing separ-
ate outcomes for HIV-positive and HIV-negative indi-
viduals. For HIV-positive individuals, we are interested
in differences between conditions in health outcomes
(retention in PMTCT and medication adherence for
women, linkage to CTC for men, and depression) and
stigma constructs (anticipated stigma, internalized
stigma, and HIV disclosure). For HIV-negative individ-
uals, we are interested in differences between conditions
in stigma constructs (attitudes to PLWH and anticipated
stigma) as well as willingness to test for HIV in the
future. Additional analyses will examine changes in
stigma attitudes by subscales (i.e., moral judgment and
social distancing) and will include stratified analysis by
gender.
For outcomes where there is a baseline measure,
mixed-effects regression analysis will be used to model
pre–post differences within and between arms, using a
time by condition model specification (time, condition,
and time × condition). Individual-level random inter-
cepts will be used to account for correlation due to re-
peated measurement. Using a mixed-effects regression
approach leaves flexibility to control for baseline out-
come values that may not be balanced between groups
due to small sample size, and may improve precision of
treatment effect estimation. For outcomes where there is
no baseline measure, we will examine differences in
means or proportions with 95% confidence intervals. If
we suspect, a priori, that baseline imbalance in prognos-
tic covariates may be an issue, we will move into a re-
gression framework. Given ACASI data collection
methods, we expect low amounts of missing data. In
cases of missing data, multiple imputation methods will
be used.
Analysis of outcomes for the HIV-negative participants
will be completed using a subsample of enrolled partici-
pants who are selected to complete a follow-up survey.
Primary analysis will be done on an intention-to-treat
(ITT) basis including all cases who were selected for a
follow-up survey. We also conduct secondary analysis on
a per-protocol (PP) basis considering only participants
who received all intervention sessions and completed
follow-up. Furthermore, sensitivity analysis will be con-
ducted to assess the effect of missing data on results.
Some interim analysis will be performed to check study
progress and monitor for adverse events. For clients who
are HIV seropositive, apart from retention in care, im-
pact on other outcomes (e.g., internalized HIV stigma)
will be assessed only among clients who completed the
baseline survey knowing their HIV status.
Monitoring
Given the low-risk nature of the counseling intervention,
we do not anticipate any adverse events as a result of
intervention exposure. Therefore, we will not have an in-
dependent data monitoring committee. The study team
will monitor adherence to the protocol and will report
any potential adverse events to the institutional review
boards. To ensure the quality of our science, we will
have daily check-ins with the field team to monitor daily
enrollment of clients, challenges or issues with the con-
senting process, and any matters arising during survey
administration and intervention delivery. The data man-
ager will do a thorough review of the data on a weekly
basis, and queries will be sent to research assistants for
clarification. Any pressing issues in need of discussion or
decision-making will be discussed with the broader team
during a weekly team call. Call minutes will be docu-
mented and shared with the full team. Due to the low
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likelihood of adverse effects as a consequence of trial
procedures, post-trial administration of counselling is
not applicable.
The depression measure that is included in the survey
includes a question that assesses for suicidal ideation [29,
30]. If the suicidal ideation question is endorsed, a coded
message will be displayed to the research staff at the end
of the assessment. The counselor will also make note if a
participant says something during a Maisha session that
indicates they are experiencing suicidal ideation. In either
of these cases where ideation is indicated, the staff will fol-
low a protocol to assess the risk, identify sources of sup-
port, make a plan for the participant’s safety, and make
referrals to clinic personnel as needed. Research staff have
been trained on procedures related to emotional distress
and the assessment of personal safety and risk, and will re-
port any adverse events to the study coordinator and the
local Principal Investigator for further follow-up.
Dissemination
A study advisory board has been established to provide
ongoing stakeholder input on the study and share emer-
ging data and findings. The board will be convened for
three half-day workshops during the study: initially, for
input on intervention content; mid-way, for feedback on
the curriculum and preliminary findings; and at the con-
clusion, for interpretation/dissemination of results. Ad-
visory board members will be sent a quarterly newsletter
with updates on the study progress.
At the conclusion of the study, we will conduct a feed-
back forum with a larger audience of stakeholders from a
variety of institutions, including clinic staff and patients,
regional representatives of the Ministry of Health, HIV ad-
vocacy and service organizations, and women’s health or-
ganizations. During the forum, the team will share the
findings of the study and facilitate a discussion about the
implications of the data for future research and practice.
Results will also be published in peer-reviewed journals
and presented at appropriate scientific meetings, including
regional, national, and international meetings. Authorship
eligibility guidelines will follow the authorship guidelines
of the International Committee for Medical Journal Edi-
tors (www.icmje.org); we do not intend to use professional
writers in the reporting of study results.
All study investigators, along with the data manage-
ment team, will have access to the final trial dataset. The
observational data may be analyzed to answer research
questions beyond our stated objectives, and researchers
from outside the team can request access to the data.
Data can be shared with a data transfer agreement from
the Tanzanian National Health Research Ethics Review
Committee and within the constraints required for the
protection of confidentiality for study subjects. Shared
data will not include identifiable information.
Study organization
As the Principal Investigators of the Maisha interven-
tion, MHW and BTM are charged with co-leading the
study. They will ensure the completion and integrity of
the study by managing and monitoring study activities
and the reporting of study findings. They will facilitate
collaboration between Duke University and KCMC by
initiating and maintaining communication between these
two institutions and the study staff at both locations.
MHW and BTM will monitor the ethical overall conduct
of research activities, and be responsible for overseeing
compliance of financial expenditures in accordance with
sponsoring agency regulations.
The faculty investigators in the study, JSN and JR, will
bring expertise on PMTCT care delivery and mental
health to the Maisha intervention. They will support the
scientific oversight of the study, meeting weekly with
study staff and providing ongoing supervision and
support.
A minimum of one data collection staff member will
be based at each of the clinical sites, and be responsible
for recruiting participants and obtaining study data
through surveys (using ACASI technology) and qualita-
tive interviews. One counselor will be based at each clin-
ical site, and will be responsible for delivering the
Maisha sessions. The data management team, led by
statistician LM at KCMC, will be responsible for storing,
analyzing, and interpreting quantitative data. The team
will clean data and code measures at each time point in
order to ensure that the data are valid and easily
interpreted.
To elicit stakeholder input, we have established a study
advisory board (see “Dissemination”) that includes repre-
sentatives from the Tanzanian Ministry of Health, leader-
ship in the study clinics, community-based organizations,
and members from the KCMC HIV Community Advisory
Board.
Discussion
Despite the significant impact of stigma on HIV care
engagement, few evidence-based interventions to address
HIV stigma exist [33–35]. The Maisha intervention is
novel because it addresses HIV stigma during the first
ANC appointment, which is a key, early juncture of HIV
care for women who test positive. Additionally, it takes
advantage of universal HIV testing of women and their
partners during the first ANC visit, and promotes
acceptance and empathy toward PLWH during the
heightened emotional period of HIV testing.
Although this study includes a large number of partici-
pants (n = 1700), it remains a pilot feasibility trial
because the estimated number of HIV-positive partici-
pants (n = 50 women) remains underpowered to evaluate
the primary outcome of retention in PMTCT care. If the
Watt et al. Trials          (2019) 20:807 Page 11 of 13
preliminary data demonstrate that the intervention is
feasible and acceptable, with potential to impact our
study outcomes, we will move forward with a full
cluster-randomized trial of the intervention in an in-
creased geographical area within the PMTCT setting. A
future study will have a larger sample size to capture
more HIV-positive women and include longer follow-up
through the postpartum period, and we will use bio-
marker outcomes to assess medication adherence and
HIV progression.
The Maisha trial was designed with consideration for
future scale-up and implementation in the Tanzanian
setting. This includes efforts to use existing clinic re-
sources, minimize additional costs, and avoid placing
burden on thinly stretched clinic providers. In this pilot
feasibility trial, we will examine the potential for inte-
grating Maisha into routine clinical care as a way to ad-
dress community-level HIV stigma and promote HIV
care engagement. We will also assess the feasibility of
delivery by Bachelor-level counselors, and examine
whether the video format of Maisha 1 will allow for effi-
cient and standardized delivery of the session content.
Future iterations of the intervention may seek to train
existing clinic staff to deliver Maisha as an enhancement
to the standard of care, and to deliver the video content
in a group format within the clinic space. Should Maisha
prove feasible and acceptable in our feasibility trial, we
will engage a broader group of stakeholders and policy-
makers to explore future scale-up.
Trial status
This trial was registered at ClinicalTrials.gov
(NCT03600142) on 25 July 2018. The first participant
was enrolled on 8 April 2019. Participant recruitment
and enrollment is ongoing and expected to be completed
by March 2020, with final follow-up expected by June
2020.
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